98 related articles for article (PubMed ID: 163723)
1. Disorders of movement: a mercifully short primer.
Weinmann RL
Dis Nerv Syst; 1975 Feb; 36(2):84-6. PubMed ID: 163723
[TBL] [Abstract][Full Text] [Related]
2. Neurochemical anatomy of movement disorders.
Young AB; Penney JB
Neurol Clin; 1984 Aug; 2(3):417-33. PubMed ID: 6152481
[TBL] [Abstract][Full Text] [Related]
3. Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms.
Hornykiewicz O
Adv Neurol; 1993; 60():140-7. PubMed ID: 8420131
[No Abstract] [Full Text] [Related]
4. [Neurobiologic and pharmacologic studies on the pathogenesis of Parkinson disease].
Brücke T; Riederer P
Wien Med Wochenschr; 1986 Aug; 136(15-16):401-8. PubMed ID: 2878540
[TBL] [Abstract][Full Text] [Related]
5. Dopaminergic and cholinergic lesions in progressive supranuclear palsy.
Ruberg M; Javoy-Agid F; Hirsch E; Scatton B; LHeureux R; Hauw JJ; Duyckaerts C; Gray F; Morel-Maroger A; Rascol A
Ann Neurol; 1985 Nov; 18(5):523-9. PubMed ID: 3000280
[TBL] [Abstract][Full Text] [Related]
6. [Movement disorders and basal ganglia function].
Dietrichs E
Tidsskr Nor Laegeforen; 2008 Sep; 128(17):1968-71. PubMed ID: 18787574
[TBL] [Abstract][Full Text] [Related]
7. Striatal dysfunction increases basal ganglia output during motor cortex activation in parkinsonian rats.
Belluscio MA; Riquelme LA; Murer MG
Eur J Neurosci; 2007 May; 25(9):2791-804. PubMed ID: 17561844
[TBL] [Abstract][Full Text] [Related]
8. Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness.
Hornykiewicz O
Neurodegener Dis; 2008; 5(3-4):114-7. PubMed ID: 18322366
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of action of short- and long-term L-DOPA treatment in parkinsonism: role of the surviving nigrostriatal dopaminergic neurons.
Melamed E; Hefti F
Adv Neurol; 1984; 40():149-57. PubMed ID: 6695591
[No Abstract] [Full Text] [Related]
10. Clinical features, diagnosis, and imaging of parkinsonian syndromes.
Poewe W
Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):333-8. PubMed ID: 8507902
[TBL] [Abstract][Full Text] [Related]
11. [Axial (neck and trunk) rigidity in Parkinson's disease, striatonigral degeneration and progressive supranuclear palsy].
Nagumo K; Hirayama K
Rinsho Shinkeigaku; 1996 Oct; 36(10):1129-35. PubMed ID: 8997136
[TBL] [Abstract][Full Text] [Related]
12. The striopallidal system: Its implication in motor disorders.
Poirier LJ; Parent A; Roberge AG
Pathobiol Annu; 1975; 5():339-67. PubMed ID: 812038
[No Abstract] [Full Text] [Related]
13. Behavioral responses and Fos activation following painful stimuli in a rodent model of Parkinson's disease.
Tassorelli C; Armentero MT; Greco R; Fancellu R; Sandrini G; Nappi G; Blandini F
Brain Res; 2007 Oct; 1176():53-61. PubMed ID: 17884026
[TBL] [Abstract][Full Text] [Related]
14. Partial depletion of dopamine in substantia nigra impairs motor performance without altering striatal dopamine neurotransmission.
Andersson DR; Nissbrandt H; Bergquist F
Eur J Neurosci; 2006 Jul; 24(2):617-24. PubMed ID: 16903863
[TBL] [Abstract][Full Text] [Related]
15. Variations in the "on-off" phenomenon.
Duvoisin RC
Adv Neurol; 1974; 5():339-40. PubMed ID: 4440582
[No Abstract] [Full Text] [Related]
16. GABA in the striatonigral and striatopallidal systems as moderator and mediator of striatal functions.
Scheel-Krüger J
Adv Neurol; 1984; 40():85-90. PubMed ID: 6141713
[No Abstract] [Full Text] [Related]
17. Three types of akinesia in the progressive course of Parkinson's disease.
Narabayashi H
Adv Neurol; 1993; 60():18-24. PubMed ID: 8093577
[No Abstract] [Full Text] [Related]
18. Compactotomy in Huntington's chorea.
Bonelli RM; Kenner L; Gruber A; Reisecker F; Költringer P
Med Hypotheses; 2001 Oct; 57(4):491-6. PubMed ID: 11601877
[TBL] [Abstract][Full Text] [Related]
19. [Morphological magnetic resonance imaging: its value for the diagnosis of neurodegenerative diseases].
Hahn U; Schwarz J; Gratz S; Kaiser JW; Jarnig M; Förstl H
Dtsch Med Wochenschr; 2008 May; 133 Suppl 1():S15-8. PubMed ID: 18437637
[TBL] [Abstract][Full Text] [Related]
20. Striatal calcium channel antagonist receptors in Huntington's disease and Parkinson's disease.
Watson DL; Carpenter CL; Marks SS; Greenberg DA
Ann Neurol; 1988 Mar; 23(3):303-5. PubMed ID: 2967667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
